Evidence map›Paper›PMID 38434063›Full record

ArticleHeliyon2024

Improved neural network with multi-task learning for Alzheimer's disease classification.

Xin Zhang, Le Gao, Zhimin Wang, Yong Yu, Yudong Zhang, Jin Hong

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xin ZhangSchool of Electronic and Information Engineering, Wuyi University, Jiangmen, 529000, China.
Le GaoSchool of Electronic and Information Engineering, Wuyi University, Jiangmen, 529000, China.
Zhimin WangSchool of Electronic and Information Engineering, Wuyi University, Jiangmen, 529000, China.
Yong YuSchool of Computer Science, Shaanxi Normal University, Xi'an, 710062, China.
Yudong ZhangSchool of Computing and Mathematic Sciences, University of Leicester, Leicester, LE17RH, UK.
Jin HongSchool of Information Engineering, Nanchang University, Nanchang, 330031, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease(AD) poses a significant challenge due to its widespread prevalence and the lack of effective treatments, highlighting the urgent need for early detection. This research introduces an enhanced neural network, named ADnet, which is based on the VGG16 model, to detect Alzheimer's disease using two-dimensional MRI slices. ADNet incorporates several key improvements: it replaces traditional convolution with depthwise separable convolution to reduce model parameters, replaces the ReLU activation function with ELU to address potential issues with exploding gradients, and integrates the SE(Squeeze-and-Excitation) module to enhance feature extraction efficiency. In addition to the primary task of MRI feature extraction, ADnet is simultaneously trained on two auxiliary tasks: clinical dementia score regression and mental state score regression. Experimental results demonstrate that compared to the baseline VGG16, ADNet achieves a 4.18% accuracy improvement for AD vs. CN classification and a 6% improvement for MCI vs. CN classification. These findings highlight the effectiveness of ADnet in classifying Alzheimer's disease, providing crucial support for early diagnosis and intervention by medical professionals. The proposed enhancements represent advancements in neural network architecture and training strategies for improved AD classification.

Indexed as

Alzheimer's diseaseMulti-task learningVGG16 network

Identifiers

PMID38434063
PMCPMC10906290

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.